Sio Capital Management LLC Acquires 621,222 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Sio Capital Management LLC grew its holdings in COMPASS Pathways plc (NASDAQ:CMPS) by 211.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 914,639 shares of the company’s stock after buying an additional 621,222 shares during the quarter. COMPASS Pathways makes up approximately 2.3% of Sio Capital Management LLC’s investment portfolio, making the stock its 15th largest holding. Sio Capital Management LLC’s holdings in COMPASS Pathways were worth $5,762,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Blue Trust Inc. bought a new position in shares of COMPASS Pathways in the second quarter worth $81,000. Green Alpha Advisors LLC bought a new position in COMPASS Pathways in the 3rd quarter worth about $99,000. Kennedy Capital Management LLC bought a new position in COMPASS Pathways in the 1st quarter worth about $139,000. Tidal Investments LLC grew its holdings in COMPASS Pathways by 43.6% during the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock valued at $159,000 after buying an additional 5,795 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in COMPASS Pathways during the 1st quarter valued at about $201,000. 46.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of analyst reports. HC Wainwright decreased their target price on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Royal Bank of Canada reduced their target price on COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Canaccord Genuity Group lowered their price target on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, August 2nd. Finally, Maxim Group cut their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $30.67.

COMPASS Pathways Price Performance

Shares of COMPASS Pathways stock opened at $4.56 on Friday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways plc has a 12 month low of $4.05 and a 12 month high of $12.75. The business’s 50-day moving average price is $5.68 and its 200-day moving average price is $6.60.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the prior year, the business earned ($0.67) earnings per share. Analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current year.

Insider Activity

In other news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the transaction, the insider now owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. This trade represents a 27.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.25% of the company’s stock.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.